BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myelogenous leukemia, driven by the tyrosine kinase gene fusion BCR–ABL1, stands out as the tumor with the most notable success in molecularly targeted therapeutics to date.